2025 China Cancer Gene Therapy Market Revenue Opportunities Report
Description
The 2025 China Cancer Gene Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer gene therapy market in China include JW Therapeutics, Fosun Kite Biotechnology, BGI Genomics, and Novartis. JW Therapeutics, founded in 2016 in partnership between US CAR-T pioneer Juno Therapeutics and Chinese manufacturer WuXi AppTec, focuses on cell-based immunotherapies for hematological cancers and solid tumors, with its CAR-T product Relma-cel under regulatory review in China. Fosun Kite Biotechnology, a joint venture between Fosun Pharma and US-based Kite Pharma (Gilead Sciences), leads in CAR-T therapy development, notably Axicabtagene Ciloleucel, also under priority review. BGI Genomics leads in gene sequencing and cancer/genetic disease testing innovations, while Novartis operates extensive R&D and manufacturing bases in China supporting oncology and immunotherapy advances.
These companies leverage China's rapidly growing biotech ecosystem, supported by heavy government investment and a strong clinical trial environment with over 700 CAR-T trials ongoing. JW Therapeutics and Fosun Kite have established commercial manufacturing facilities in China and are advancing multiple CAR-T candidates. BGI harnesses genomic data to enhance personalized cancer therapies, and Novartis focuses on innovative drug launches and digital health integration. Domestic firms like JW Therapeutics and Fosun Kite exemplify successful Sino-foreign collaboration, propelling the cancer gene therapy field forward in China with novel treatments targeting hematological malignancies and solid tumors, underscoring China’s expanding leadership in this sector.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the cancer gene therapy market in China include JW Therapeutics, Fosun Kite Biotechnology, BGI Genomics, and Novartis. JW Therapeutics, founded in 2016 in partnership between US CAR-T pioneer Juno Therapeutics and Chinese manufacturer WuXi AppTec, focuses on cell-based immunotherapies for hematological cancers and solid tumors, with its CAR-T product Relma-cel under regulatory review in China. Fosun Kite Biotechnology, a joint venture between Fosun Pharma and US-based Kite Pharma (Gilead Sciences), leads in CAR-T therapy development, notably Axicabtagene Ciloleucel, also under priority review. BGI Genomics leads in gene sequencing and cancer/genetic disease testing innovations, while Novartis operates extensive R&D and manufacturing bases in China supporting oncology and immunotherapy advances.
These companies leverage China's rapidly growing biotech ecosystem, supported by heavy government investment and a strong clinical trial environment with over 700 CAR-T trials ongoing. JW Therapeutics and Fosun Kite have established commercial manufacturing facilities in China and are advancing multiple CAR-T candidates. BGI harnesses genomic data to enhance personalized cancer therapies, and Novartis focuses on innovative drug launches and digital health integration. Domestic firms like JW Therapeutics and Fosun Kite exemplify successful Sino-foreign collaboration, propelling the cancer gene therapy field forward in China with novel treatments targeting hematological malignancies and solid tumors, underscoring China’s expanding leadership in this sector.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
